All In Biotech

Drug Trial Radar · NCT07785063

Efficacy, Safety and Pharmacokinetics of LP-003 in Peanut Allergic Patients

A Randomized, Double-Blind, Placebo-Controlled Phase Ⅱ Clinical Study to Evaluate the Efficacy, Safety and Pharmacokinetics of LP-003 in Peanut Allergic Patients

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

May 2029

Study completion Nov 2029

Sponsor

Sponsor type
Industry
First posted
Aug 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of LP-003 for an increasing the amount of peanut protein that people with a peanut allergy can tolerate without having allergic symptoms. The study will include participants 12 to 55 years of age with a confirmed peanut allergy. Participants will be randomly assigned to receive LP-003 or placebo. LP-003 will be given by an injection under the skin (subcutaneous) once every 8 weeks during the first 24 weeks of treatment. Participants will not know the treatment they are receiving until the end of the study. The primary efficacy endpoints will be the proportion of participants in each group who successfully consume a single dose of ≥600 mg of peanut protein during a supervised double-blind, placebo-controlled food challenge at Week 24. Participants who complete the 24 weeks will continue for another 24 weeks in a blinded (participants will not know what treatment they are on) extension period, followed by a blinded follow-up period for continued safety, pharmacokinetic, pharmacodynamic, and immunogenicity assessments. The total study duration for each participant is approximately 84 weeks.

Conditions

  • Peanut Allergies

Interventions

  • LP-003 InjectionDrug

    The active ingredient of LP-003 Injection is a humanized anti-IgE monoclonal antibody. There are two dose groups, 300mg and 600mg: each administered as a subcutaneous injection site, Q8W.

  • Placebo InjectionDrug

    Placebo is a sterile injectable solution matched to LP-003 for appearance, formulation, and administration, with 0 mg of active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Patients Without Dose Limiting SymptomsTime frame: From initial administration of the investigational product (Day1) up to and including Week 24 (Day 141).

Locations

13 sites in 4 countries. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Cenexel Marlton

    Marlton, New Jersey

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Murdoch Children's Research Institute

    Parkville, Victoria, Australia

  • Perth Children's Hospital

    Nedlands, Western Australia, Australia

  • Fiona Stanley Hospital

    Perth, Western Australia, Australia

  • Halton Pediatric Allergy

    Burlington, Ontario, Canada

  • Triple A Labs

    Hamilton, Ontario, Canada

  • University of McMaster

    Hamilton, Ontario, Canada

  • Allergy Research Canada

    Niagara Falls, Ontario, Canada

  • University of Montreal

    Montreal, Quebec, Canada

  • The Capital Region Allergy Clinic

    Québec, Quebec, Canada

  • The Chinese University of Hong Kong Clinical Trial Centre

    Hong Kong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.